Studies on the antimalarial property of 4-methoxy-6-sulfanilamido-pyrimidine monohydrate (sulfamonomethoxine: DJ-1550) and on its effect on the chloroquine-resistant malaria.
D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use*; D003864:Depression, Chemical; D004912:Erythrocytes / Q000382:microbiology; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D010965:Plasmodium malariae / Q000187:drug effects / Q000302:isolation & purification; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000627:therapeutic use; D013412:Sulfadimethoxine / Q000627:therapeutic use; D013416:Sulfamerazine / Q000627:therapeutic use; D013418:Sulfamethazine / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*
D000962:Antimalarials; D011743:Pyrimidines; D013449:Sulfonamides; D013411:Sulfadiazine; D013412:Sulfadimethoxine; D013418:Sulfamethazine; D002738:Chloroquine; D013416:Sulfamerazine